Cancer Gene Therapy Week articles from November 2004

Cancer Gene Therapy Week archives from November 2004

Chimeric constructs target heterologous genes in cancer-derived cells.
November 1, 2004... 2004 NOV 1 - (NewsRx.com & NewsRx.net) -- Chimeric constructs target heterologous genes in cancer-derived cells. "EGP-2, also known as Ep-CAM, is expressed at high levels on the surface of most carcinomas and is therefore considered an...

Viral properties can be incorporated into adenovirus-based cancer therapies.
November 1, 2004... 2004 NOV 1 - (NewsRx.com & NewsRx.net) -- Viral properties can be incorporated into adenovirus-based cancer therapies. According to recent research from the United States, "apoptotic pathways are initiated as a cellular defense mechanism...

Loss of clone with FLT3 gene mutation at relapse does not improve AML prognosis.
November 1, 2004... 2004 NOV 1 - (NewsRx.com & NewsRx.net) -- The loss of a clone with an FLT3 gene mutation at relapse does not improve the prognosis of acute myeloid leukemia. According to recent research from Germany, "Internal tandem duplications (ITDs)...

Gli proteins up-regulate expression of basonuclin in basal cell carcinoma.
November 1, 2004... 2004 NOV 1 - (NewsRx.com & NewsRx.net) -- Gli proteins up-regulate the expression of basonuclin in basal cell carcinoma. "Tumorigenesis is frequently accompanied by enhanced rRNA transcription, but the signaling mechanisms responsible for...

Genetic tumor virulence markers identified in murine model.
November 1, 2004... 2004 NOV 1 - (NewsRx.com & NewsRx.net) -- Genetic markers of tumor virulence have been identified in a murine model of breast cancer. "FVB/N-Tg (MMTV-PyMT)[superscript]634Mul-transgenic mice develop multifocal mammary tumors with a high...

The adenoviral type 5 E1A gene sensitizes breast tumors to paclitaxel.
November 1, 2004... 2004 NOV 1 - (NewsRx.com & NewsRx.net) -- The adenoviral type 5 E1A gene sensitizes breast tumors to paclitaxel. "Paclitaxel (Taxol) is a promising frontline chemotherapeutic agent for the treatment of human breast and ovarian cancers. The...

Well-differentiated breast tumors have more 16q loss than poorly differentiated.
November 1, 2004... 2004 NOV 1 - (NewsRx.com & NewsRx.net) -- Well-differentiated breast tumors have more 16q loss than poorly differentiated tumors. According to a study from the Netherlands, "Loss of heterozygosity (LOH) at the long arm of chromosome 16 is a...

Cancer research foundation announces new partnership.
November 1, 2004... 2004 NOV 1 - (NewsRx.com & NewsRx.net) -- The Lance Armstrong Foundation (LAF) has announced a 5-year, $500,000 gift to the Nevada Cancer Institute (NVCI) to establish the Lance Armstrong Foundation Survivorship Center at the Institute. The new...

Pharmacological unmasking microarray identifies tumor suppressor genes.
November 1, 2004... 2004 NOV 1 - (NewsRx.com & NewsRx.net) -- A novel microarray analysis technique facilitates the identification of tumor suppressor genes. "Aberrant promoter hypermethylation of tumor suppressor genes is proposed to be a common feature of...

Biopharma company announces update on trial of compound for advanced cancers.
November 1, 2004... 2004 NOV 1 - (NewsRx.com & NewsRx.net) -- NeoPharm (Nasdaq:NEOL) announced that results from a phase I clinical trial of the company's NeoLipid compound LE-SN38 in patients with advanced cancers were presented at the 16th Symposium on Molecular...

Icelandic technology fund to support collaborative cancer diagnostics project.
November 1, 2004... 2004 NOV 1 - (NewsRx.com & NewsRx.net) -- The Technology Development Fund of Iceland has decided to support a project aiming for the development of a new technology for diagnosing cancer. The project is to be performed by scientists at...

Leukemia society awards two $5 million grants to develop anticancer therapies.
November 1, 2004... 2004 NOV 1 - (NewsRx.com & NewsRx.net) -- The Leukemia & Lymphoma Society awarded two Specialized Center of Research (SCOR) grants, bringing funding for the program, the society's most synergistic research initiative, past $77 million in the 5...

Data supports value of prostate brachytherapy.
November 1, 2004... 2004 NOV 1 - (NewsRx.com & NewsRx.net) -- Recent data from a 12-year follow-up of more than 1,500 patients showed brachytherapy as a powerful treatment for prostate cancer. Dr. Louis Potters, medical director of the New York Prostate...

Biogen enters pharmacodiagnostic research collaboration.
November 1, 2004... 2004 NOV 1 - (NewsRx.com & NewsRx.net) -- Epigenomics, AG, (ECX), a molecular diagnostic company developing tests based on DNA methylation, announced that the company has entered into a research collaboration with Biogen Idec (BIIB) to identify...

p53-dependent transcription exhibits on and off responses after genotoxic stress.
November 1, 2004... 2004 NOV 1 - (NewsRx.com & NewsRx.net) -- p53-dependent transcription exhibits both on and off responses after genotoxic stress. According to published research from Estonia, "The p53 protein is a central player in cellular response to DNA...

Expression of 7 ARP2/3 complex genes are decreased in gastric cancer.
November 1, 2004... 2004 NOV 1 - (NewsRx.com & NewsRx.net) -- The expression of 7 ARP2/3 complex genes are decreased in gastric cancers. "The Arp2/3 complex and filamins play important roles in organization of actin cytoskeleton, and thus in cellular...

KiSS-1 downregulation causes tumor invasion/worse prognosis in gastric cancer.
November 1, 2004... 2004 NOV 1 - (NewsRx.com & NewsRx.net) -- KiSS-1 downregulation causes tumor invasion and a worse prognosis in gastric cancer. According to recent research from Japan, "KiSS-1 is a promising candidate tumor-suppressor gene and may play a...

Biological materials provider signs distribution agreement with GE Healthcare.
November 1, 2004... 2004 NOV 1 - (NewsRx.com & NewsRx.net) -- SeraCare Life Sciences, Inc. (SeraCare), and its Genomics Collaborative (GCI) division, has entered into a 3-year strategic distribution alliance with GE Healthcare (a combination of the former Amersham...

New grant awarded for anemia treatment.
November 1, 2004... 2004 NOV 1 - (NewsRx.com & NewsRx.net) -- Gene therapy research company Mirus Bio announced that it has been awarded a $1.26 million, multi-year Phase II Small Business Innovation Research (SBIR) grant from the U.S. National Institutes of...

Research company collaborates with scientists on BAC clone from tomato genome.
November 1, 2004... 2004 NOV 1 - (NewsRx.com & NewsRx.net) -- wrightHung Ma 800-720-4363 SeqWright, Inc., a contract research organization specializing in genomics-based services, announced a collaborative agreement to sequence 400,000 bacterial artificial...

Protein patterns can be used to identify GBM subtypes.
November 1, 2004... 2004 NOV 1 - (NewsRx.com & NewsRx.net) -- Protein expression patterns can be used to identify subtypes of glioblastoma multiforme (GBM). According to recent research from the United States, GBM "has been subdivided into two types based on...

Government should spend more to fight cancer, 89% of survey respondents say.
November 1, 2004... 2004 NOV 1 - (NewsRx.com & NewsRx.net) -- While the federal government has allocated nearly $5 billion for cancer research this year, many Americans don't believe it is enough. Eighty-nine percent of respondents to a recent survey conducted...

Gene expression patterns with prognostic value identified.
November 1, 2004... 2004 NOV 1 - (NewsRx.com & NewsRx.net) -- Gene expression profiles with prognostic value in hepatocellular carcinoma (HCC) have been identified. In a recent study, hepatologists in the United States, "analyzed global gene expression...

Drug receives orphan designation.
November 1, 2004... 2004 NOV 1 - (NewsRx.com & NewsRx.net) -- Medarex (MEDX) announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to Medarex's fully human anti-CD30 antibody, MDX-060, for the treatment of Hodgkin's...

Cancer center utilizes new CT technology.
November 1, 2004... 2004 NOV 1 - (NewsRx.com & NewsRx.net) -- Siemens (SI) announced that the University of Texas M. D. Anderson Cancer Center will acquire five new CT systems, which will be installed in the new Ambulatory Care Building at the M.D. Anderson Cancer...

B-RAF is therapeutic target in melanoma.
November 1, 2004... 2004 NOV 1 - (NewsRx.com & NewsRx.net) -- B-RAF is a therapeutic target in melanoma. According to a study from England, "B-RAF is a serine/threonine-specific protein kinase that is mutated in approximately 70% of human melanomas. However,...

Anticancer agent may help induce cancer cell death.
November 1, 2004... 2004 NOV 1 - (NewsRx.com & NewsRx.net) -- Maxim Pharmaceuticals (MAXM) reported that in preclinical studies, its anticancer agent, MX22167, targets the transferrin receptor, leading to a previously unknown rapid induction of apoptosis. The...

FDA grants fast-track designation for metastatic melanoma treatment.
November 1, 2004... 2004 NOV 1 - (NewsRx.com & NewsRx.net) -- Medarex (MEDX) announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for Medarex's fully human antibody against human CTLA-4, MDX-010 in combination with...

Phase II trial slated for renal cancer treatment.
November 1, 2004... 2004 NOV 1 - (NewsRx.com & NewsRx.net) -- Biopharmaceutical company MethylGene (MYG) announced that a randomized, 2-step Phase II clinical trial with MG98 in combination with interferon alpha for the treatment of metastatic renal cell cancer....

Pre-clinical results show promise for cancer treatment.
November 1, 2004... 2004 NOV 1 - (NewsRx.com & NewsRx.net) -- MorphoSys (MOR) presented preclinical results from its internal cancer antibody program, MOR202. MorphoSys said that the MOR202 antibodies were initially characterized in detail in various in vitro...

Restoration of metastasis suppressor genes could abate cancer dissemination.
November 1, 2004... 2004 NOV 1 - (NewsRx.com & NewsRx.net) -- Restoration of metastasis suppressor genes could abate cancer dissemination. "The metastatic cascade is a complicated process that involves many steps from gain of the metastatic phenotype in the...

Trichostatin A offers novel therapeutic strategy for osteosarcoma.
November 1, 2004... 2004 NOV 1 - (NewsRx.com & NewsRx.net) -- Trichostatin A offers a novel therapeutic strategy for treating osteosarcoma. "Although histone deacetylase (HDAC) inhibitors are emerging as a promising new treatment strategy in malignancy, how...

Suppressed synthesis of HMGA1 protein treats pancreatic carcinomas in mice.
November 1, 2004... 2004 NOV 1 - (NewsRx.com & NewsRx.net) -- Suppressed synthesis of HMGA1 protein treats pancreatic carcinomas in mice. According to a study from Italy, "pancreatic carcinoma is one of the most aggressive tumors, and, being refractory to...

Biopharma company appoints vice president clinical research and development.
November 1, 2004... 2004 NOV 1 - (NewsRx.com & NewsRx.net) -- Conforma Therapeutics Corporation announced the appointment of Robert L. De Jager, MD, FACP, to the newly created position of vice president, clinical research and development and chief medical officer....

Cancer diagnostic company announces new research and development executive.
November 1, 2004... 2004 NOV 1 - (NewsRx.com & NewsRx.net) -- Matritech (MZT) announced the election of Gary Fagan, Ph.D., as vice president of research and development. Prior to this appointment, Fagan was Matritech's senior director of product development,...

Pharmaceuticals names cancer researchers, clinicians to advisory board.
November 1, 2004... 2004 NOV 1 - (NewsRx.com & NewsRx.net) -- Semafore Pharmaceuticals, Inc., a developer of small molecule cancer therapies addressing critical cell signaling pathways, announced additions to its Scientific and Clinical Advisory Board. ...

Life sciences company, Rubicon Genomics sign genome amplification agreement.
November 1, 2004... 2004 NOV 1 - (NewsRx.com & NewsRx.net) -- Sigma-Aldrich (SIAL), a life science and high technology company, has announced an exclusive licensing agreement with Rubicon Genomics, a molecular diagnostics company. The companies agreed to...

EPHB2 mutations linked to aggressive disease.
November 1, 2004... 2004 NOV 1 - (NewsRx.com & NewsRx.net) -- EPHB2 mutations are associated with aggressive disease in prostate cancer patients. "The identification of tumor-suppressor genes in solid tumors by classical cancer genetics methods is difficult...

Mechanisms of perineural invasion elucidated.
November 1, 2004... 2004 NOV 1 - (NewsRx.com & NewsRx.net) -- The molecular mechanisms of perineural invasion (PNI) in prostate cancer have been elucidated. PNI is "the major mechanism of prostate cancer spread outside the prostate," oncologists in Texas...

New report evaluates importance of cell therapy.
November 1, 2004... 2004 NOV 1 - (NewsRx.com & NewsRx.net) -- A new report from Research and Markets evaluates the importance and potential impact of stem cell research and therapy. The report describes different cell therapy technologies, discusses the ethical...

Low-voltage electroporation augments antiangiogenic cancer gene therapy.
November 1, 2004... 2004 NOV 1 - (NewsRx.com & NewsRx.net) -- Low-voltage electroporation augments antiangiogenic cancer gene therapy. According to a study from Japan, "antiangiogenic factors are potent endothelial cell growth inhibitors that have been shown...

Herpesvirus-based vector guides fusion protein to cancer cells.
November 1, 2004... 2004 NOV 1 - (NewsRx.com & NewsRx.net) -- Herpesvirus-based vector guides fusion protein to cancer cells. "Herpesvirus saimiri (HVS) has the capacity to incorporate large amounts of heterologous DNA and can infect many different human cell...

A new multicomponent drug delivery system sensitizes lung cancer to therapy.
November 8, 2004... 2004 NOV 8 - (NewsRx.com & NewsRx.net) -- A new multicomponent drug delivery system sensitizes lung cancer to therapy. "The efficacy of chemotherapy of lung cancer is limited by the development of resistance in cancer cells during...

Nanosecond pulsed electric fields could augment cancer and gene therapy.
November 8, 2004... 2004 NOV 8 - (NewsRx.com & NewsRx.net) -- Nanosecond pulsed electric fields could augment cancer and gene therapy. "These studies describe the effects of nanosecond (10-300 ns) pulsed electric fields (nsPEF) on mammalian cell structure and...

Mutation hotspots in p53 gene depend on tumor type and cell growth conditions.
November 8, 2004... 2004 NOV 8 - (NewsRx.com & NewsRx.net) -- Mutation hotspots in the p53 gene depend on the tumor type and cell growth conditions. "We present a classification analysis of the mutation spectra of the p53 gene and construct maps of hotspots...

The methylation inhibitor zebularine selectively targets cancer cells.
November 8, 2004... 2004 NOV 8 - (NewsRx.com & NewsRx.net) -- The methylation inhibitor zebularine selectively targets cancer cells. According to a study from the United States, "the frequent silencing of tumor suppressor genes by altered cytosine methylation...

The SV40 enhancer and the HTERT gene promoter improve cancer gene therapy.
November 8, 2004... 2004 NOV 8 - (NewsRx.com & NewsRx.net) -- The SV40 enhancer and the HTERT gene promoter improve cancer gene therapy. "Telomerase is a ribonucleoprotein complex of which the function is to add telomeric repeats to chromosomal ends....

Government to provide more funding for Anthim, an antianthrax drug.
November 8, 2004... 2004 NOV 8 - (NewsRx.com & NewsRx.net) -- Elusys Therapeutics, Inc., announced that the federal government will provide additional funding for Anthim, the company's antibody treatment for exposure to anthrax toxin. Elusys will receive $5...

Ninety-seven grants awarded to breast cancer scientists and researchers.
November 8, 2004... 2004 NOV 8 - (NewsRx.com & NewsRx.net) -- In celebration of its tenth anniversary, The Breast Cancer Research Foundation (BCRF) awarded over $18 million to 97 renowned and respected breast cancer scientists and researchers. This year's...

Promoter methylation of PTEN gene is common molecular change in breast cancer.
November 8, 2004... 2004 NOV 8 - (NewsRx.com & NewsRx.net) -- Promoter methylation of the PTEN gene is a common molecular change in breast cancer. "About 25-50% of women with Cowden disease, a syndrome associated with germ-line mutations of the PTEN gene (at...

Imatinib sensitivity predicted by testing Wilms tumor gene expression.
November 8, 2004... 2004 NOV 8 - (NewsRx.com & NewsRx.net) -- Imatinib sensitivity has been predicted by testing Wilms tumor gene expression. "The objective of the current study was to verify the ability to predict response to imatinib therapy using in vitro...

Novel transplatinum drug ATZ interferes with topoisomerase I in cancer cells.
November 8, 2004... 2004 NOV 8 - (NewsRx.com & NewsRx.net) -- A novel transplatinum drug, ATZ, interferes with topoisomerase I in breast and ovarian cancer cells. According to published research from the United States, "Cisplatin, cis-[PtCl2(NH3)(2)], is...

Partnership restructures agreement to develop protein to aid in heart surgeries.
November 8, 2004... 2004 NOV 8 - (NewsRx.com & NewsRx.net) -- Millennium Pharmaceuticals and XOMA announced that they are restructuring their agreement related to the development of MLN2222, currently being investigated in a phase I clinical trial for coronary...

Partnership to allow hospital and university system to share resources.
November 8, 2004... 2004 NOV 8 - (NewsRx.com & NewsRx.net) -- The University of Houston System and The Methodist Hospital have taken the first step in forming a long-term affiliation, expanding health science and medical education programs as well as enhancing...

Bioassays company announces U.S. Army contract, new kinase Activity Assays.
November 8, 2004... 2004 NOV 8 - (NewsRx.com & NewsRx.net) -- QTL Biosystems announced the introduction of its QTL LightSpeed Kinase platform and four new kinase Activity Assays. The kinase platform is built utilizing QTL's patented superquenching polymer...

Utility of BAC arrays reviewed.
November 8, 2004... 2004 NOV 8 - (NewsRx.com & NewsRx.net) -- The utility of bacterial artificial chromosome (BAC) arrays has been reviewed. "Chromosome analysis has been a cornerstone both for the identification of genetic defects that predispose to a variety...

Utility of microarrays in cytogenetic analysis reviewed.
November 8, 2004... 2004 NOV 8 - (NewsRx.com & NewsRx.net) -- The utility of microarrays in cytogenetic analyses has been reviewed. "With the advent of array-based comparative genomic hybridization technology, the analog cytogenetic analysis that has been...

DNA vaccine trial initiated for treatment of herpes simplex type 2.
November 8, 2004... 2004 NOV 8 - (NewsRx.com & NewsRx.net) -- PowderMed Ltd (PowderMed) announced that it has initiated a phase I trial in patients of a novel therapeutic DNA vaccine for the treatment of herpes simplex type 2 (HSV2). This therapeutic vaccine...

Hepatocyte growth factor sustains grafts after bone marrow transplantation.
November 8, 2004... 2004 NOV 8 - (NewsRx.com & NewsRx.net) -- Hepatocyte growth factor sustains grafts after bone marrow transplantation. According to a study from Japan, "graft-versus-host disease (GVHD) is a major complication of allogeneic bone marrow...

Genzyme gets license for human genetic testing applications.
November 8, 2004... 2004 NOV 8 - (NewsRx.com & NewsRx.net) -- Genetic Technologies, Ltd., (GNTLY) (GTG) has granted a license to Genzyme Corp. (GENZ) for human testing applications as part of the first step in a new collaboration. Under the license agreement,...

Altered 14-3-3sigma/TEF1delta gene expression involved in lung carcinogenesis.
November 8, 2004... 2004 NOV 8 - (NewsRx.com & NewsRx.net) -- Altered 14-3-3sigma and TEF1delta gene expression may be involved in lung carcinogenesis. According to recent research from the United States, "Lung cancer, a leading cause of cancer deaths,...

European approval granted for new breast implant.
November 8, 2004... 2004 NOV 8 - (NewsRx.com & NewsRx.net) -- Mentor Corporation (MNT) announced that it received European Union Class III CE Mark approval for its Contour Profile Becker 35 Expander/Implant, a combination tissue expander and a long-term implant...

Mechanism discovered for muscle wasting seen in diabetes, AIDS, other diseases.
November 8, 2004... 2004 NOV 8 - (NewsRx.com & NewsRx.net) -- Muscle wasting is associated with aging and a serious consequence of different diseases, including cancer and diabetes. Researchers at Joslin Diabetes Center, with the assistance of other...

Partial pressure of oxygen fluctuations influence tumor dynamics.
November 8, 2004... 2004 NOV 8 - (NewsRx.com & NewsRx.net) -- Partial pressure of oxygen fluctuations influence tumor dynamics. According to recent research published in the journal Cancer Research, "the primary purpose of this study was to examine the...

Biotech updates FDA status on two cancer treatments.
November 8, 2004... 2004 NOV 8 - (NewsRx.com & NewsRx.net) -- Neoprobe Corporation has provided an update on the regulatory status of its two oncology product clinical development programs - radiopharmaceutical products RIGScan CR and Lymphoseek. RIGScan CR...

Cancer coalition donates pharmaceuticals to Mexico.
November 8, 2004... 2004 NOV 8 - (NewsRx.com & NewsRx.net) -- The National Cancer Coalition (NCC), a not-for-profit cancer group, announced that it has shipped cancer pharmaceuticals to hospitals in Mexico that serve needy oncology patients. NCC President...

FDA approves abbreviated drug application for carboplatin injection.
November 8, 2004... 2004 NOV 8 - (NewsRx.com & NewsRx.net) -- Mayne Pharma has announced that the U.S. Food and Drug Administration (FDA) has approved Mayne's Abbreviated New Drug Application for carboplatin injection. Stuart Hinchen, Mayne Pharma's president...

Inflammatory killing of normal cells might treat established tumors.
November 8, 2004... 2004 NOV 8 - (NewsRx.com & NewsRx.net) -- Inflammatory killing of normal cells might treat established tumors. According to researchers in the United States, "we describe a simple technology used to cure an established metastatic disease....

New online tool to help teens cope with cancer.
November 8, 2004... 2004 NOV 8 - (NewsRx.com & NewsRx.net) -- The Leukemia and Lymphoma Society has a new online tool designed to help teens with cancer cope with their illness. Called the Coping with Chemo Webisodes, the online tool consists of a series of...

Novel adenoviral regulation drives gene expression in prostate cancer cells.
November 8, 2004... 2004 NOV 8 - (NewsRx.com & NewsRx.net) -- Novel adenoviral regulation drives gene expression in prostate cancer cells. According to recent research from the United States, "development of novel therapeutic agents is needed to address the...

Preclinical results announced for multiple myeloma treatment.
November 8, 2004... 2004 NOV 8 - (NewsRx.com & NewsRx.net) -- MorphoSys announced promising initial in-vitro and in-vivo data for the internal cancer antibody program MOR202. The fully-human antibodies generated from MorphoSys' HuCAL GOLD library, are...

Synergy between DAC and cancer therapy fights lung cancer cell growth.
November 8, 2004... 2004 NOV 8 - (NewsRx.com & NewsRx.net) -- Synergy between DAC and cancer therapy fights lung cancer cell growth. "Treating lung cancer cell lines using low-dose 5-aza-2'-deoxycytidine (DAC) caused an accumulation of procaspase-9 through...

UK companies to develop toolkit for cancer drug assessment.
November 8, 2004... 2004 NOV 8 - (NewsRx.com & NewsRx.net) -- Medical Solutions plc (MLS) announced an alliance with Cancer Research Technology (CRT) to enhance the speed and reliability of early cancer drug development. CRT is the technology transfer and...

Jill M. Church appointed as chief financial officer by biopharm research company.
November 8, 2004... 2004 NOV 8 - (NewsRx.com & NewsRx.net) -- Vical Incorporated announced the appointment of Jill M. Church as vice president, chief financial officer and secretary. Since February 1999, Church has been vice president of finance and...

Adenoviruses with alternate serotypes transduce glioma cell lines.
November 8, 2004... 2004 NOV 8 - (NewsRx.com & NewsRx.net) -- Adenoviruses with alternate serotypes transduce glioma cell lines. According to a study from Sweden, "there is a need for improvement of the commonly used adenovirus vectors based on serotype 5....

Epigenetic changes in hematopoietic malignancies offer novel treatment tactics.
November 15, 2004... 2004 NOV 15 - (NewsRx.com & NewsRx.net) -- Epigenetic changes in hematopoietic malignancies offer novel treatment tactics. "The term epigenetic refers to a heritable change in gene expression that is mediated by mechanisms other than...

Effects of tumor E-cadherin mutations on Wnt signaling determined.
November 15, 2004... 2004 NOV 15 - (NewsRx.com & NewsRx.net) -- The impact of tumor-associated E-cadherin mutations on Wnt signaling has been determined. "E-cadherin is a cell-cell adhesion molecule and tumor invasion suppressor gene that is frequently altered...

Gene expression profiles yield clinicopathological staging of colorectal cancer.
November 15, 2004... 2004 NOV 15 - (NewsRx.com & NewsRx.net) -- Gene expression profiles yield clinicopathological staging of colorectal cancer. According to recent research from Germany, "gene expression profiling of matched colorectal carcinomas and...

New cancer target the focus of monoclonal antibody treatment.
November 15, 2004... 2004 NOV 15 - (NewsRx.com & NewsRx.net) -- OriGene Technologies and MacroGenics announced a new license agreement for a cancer target initially identified with OriGene's HTP-Rapid-Scan technology. Under the agreement, MacroGenics has the...

AMID may be a p53-downstream gene involved in tumorigenesis.
November 15, 2004... 2004 NOV 15 - (NewsRx.com & NewsRx.net) -- AMID may be a p53-downstream gene involved in tumorigenesis. "AMID, also called PRG3, is an AIF-homologous and mitochondria-associated protein that has been implicated in caspase-independent...

N-acetyltransferase 1 involved in arylamine activation.
November 15, 2004... 2004 NOV 15 - (NewsRx.com & NewsRx.net) -- N-acetyltransferase 1 is more heavily involved than its counterpart in bladder carcinogenic arylamine activation. In a recent study from Japan, "[h]uman acetyltransferase genes NAT1 or NAT2 were...

Biotransformation enzyme gene variants linked to high breast cancer risk.
November 15, 2004... 2004 NOV 15 - (NewsRx.com & NewsRx.net) -- Polymorphisms in biotransformation enzyme genes can heighten the risk of breast cancer. In a recent study, scientists in the Czech Republic sought to determine "whether any association exists...

Oncostatin M induces S100A9 gene expression in breast tumor cells.
November 15, 2004... 2004 NOV 15 - (NewsRx.com & NewsRx.net) -- The anti-cancer cytokine oncostatin M induces S100A9 gene expression in breast tumor cells. OM "strongly inhibits the growth of MCF-7 breast cancer cells through the STAT3 signaling pathway,"...

San Diego Susan Komen foundation affiliate presents 'Bras Down Broadway'.
November 15, 2004... 2004 NOV 15 - (NewsRx.com & NewsRx.net) -- Local San Diego, California, breast cancer survivors participated in the Susan G. Komen Breast Cancer Foundation's first ever Bras Down Broadway event. More than 50 breast cancer survivors donning...